Research Paper Volume 13, Issue 18 pp 22588—22610

GPR43 regulation of mitochondrial damage to alleviate inflammatory reaction in sepsis

GPR43 agonist is involved in sepsis-induced inflammatory reactions through trigger NLRP3 inflammasome. Survival rate (A) in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) for 72 h; W/D rate (B), lung injury score (C) and lung tissue using HE staining (D) in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) for 24 h; IL-6/IL-10 levels in tissue of CLP mice (E) in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) for 24 h; IL-6/IL-10 levels in serum of CLP mice (F) in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) for 24 h; Representative electron microscopy images and area void of cristae (minimum of 40 mitochondria) was used to measure mitochondrial cristae density in macrophage CLP of mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) (G) for 24 h; Representative electron microscopy images and area void of cristae (minimum of 40 mitochondria) was used to measure mitochondrial cristae density in macrophage CLP of mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) (H) for 24 h; NLRP3, Caspase-1 and IL-1β protein expressions in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) (I) for 24 h; NLRP3, Caspase-1 and IL-1β protein expressions in GPR43-/- mice of CLP (J) for 24 h; Serum IL-1β and SOD levels in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) (K, L) for 24 h; Serum IL-1β and SOD levels in GPR43-/- mice of CLP (M, N) for 24 h. Sepsis+control, CLP mice with normal saline; Sepsis+GRP43 a, CLP mice with i GPR43 agonist (4-CMTB, 10 mg/kg, i.p.); WT, WT mice with CLP; GPR43-/-, GPR43-/- mice with CLP. ##p

Figure 2. GPR43 agonist is involved in sepsis-induced inflammatory reactions through trigger NLRP3 inflammasome. Survival rate (A) in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) for 72 h; W/D rate (B), lung injury score (C) and lung tissue using HE staining (D) in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) for 24 h; IL-6/IL-10 levels in tissue of CLP mice (E) in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) for 24 h; IL-6/IL-10 levels in serum of CLP mice (F) in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) for 24 h; Representative electron microscopy images and area void of cristae (minimum of 40 mitochondria) was used to measure mitochondrial cristae density in macrophage CLP of mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) (G) for 24 h; Representative electron microscopy images and area void of cristae (minimum of 40 mitochondria) was used to measure mitochondrial cristae density in macrophage CLP of mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) (H) for 24 h; NLRP3, Caspase-1 and IL-1β protein expressions in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) (I) for 24 h; NLRP3, Caspase-1 and IL-1β protein expressions in GPR43-/- mice of CLP (J) for 24 h; Serum IL-1β and SOD levels in CLP mice with GPR43 agonist (4-CMTB, 10 mg/kg, i.p.) (K, L) for 24 h; Serum IL-1β and SOD levels in GPR43-/- mice of CLP (M, N) for 24 h. Sepsis+control, CLP mice with normal saline; Sepsis+GRP43 a, CLP mice with i GPR43 agonist (4-CMTB, 10 mg/kg, i.p.); WT, WT mice with CLP; GPR43-/-, GPR43-/- mice with CLP. ##p<0.01 compared with WT mice with CLP or ##p<0.01 compared with CLP mice with normal saline.